Hostname: page-component-6bf8c574d5-l72pf Total loading time: 0 Render date: 2025-03-05T09:27:55.613Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine-Associated Agranulocytosis: Risk and Aetiology

Published online by Cambridge University Press:  06 August 2018

P. Krupp  and
P. Barnes
P. Krupp*
Affiliation:
Clinical Research and Development, Sandoz Pharma Ltd, Postfach, CH-4002 Basel, Switzerland
P. Barnes
Affiliation:
Clinical Research and Development, Sandoz Pharma Ltd, Postfach, CH-4002 Basel, Switzerland
*
Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

This paper reviews the epidemiology and pathogenesis of clozapine-associated agranulocytosis. According to present clinical experience, granulocytopenia can be expected in approximately 3% of patients during clozapine treatment. The risk of serious sequelae of granulocytopenia can be minimised by regular white blood cell count monitoring. Although research suggests that some patient groups may be at higher risk of developing this serious adverse reaction, we cannot yet predict the susceptible patients, so all patients exposed to clozapine should receive regular blood monitoring throughout treatment. Because of the risk of agranulocytosis, clozapine should only be used in schizophrenic patients who are resistant to, or intolerant of, conventional antipsychotic medications. Unless compliance with blood monitoring is assured, clozapine treatment should not be recommended.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 160 , Issue S17: Clozapine - The Atypical Antipsychotic , May 1992 , pp. 38 - 40
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anderman, B. & Griffith, R. W. (1977) Clozapine-induced agranulocytosis: a situation report up to August 1976. European Journal of Clinical Pharmacology, 11, 199–201.Google Scholar
Baldessarini, R. J. & Frankenburg, F. R. (1991) Clozapine. A novel antipsychotic agent. The New England Journal of Medicine, 324, 746–754.Google ScholarPubMed
Balon, R. & Berchou, R. (1986) Hematologic side effects of psychotropic drugs. Psychosomatics, 27, 119–127.CrossRefGoogle ScholarPubMed
Claas, F. H. J., Abbott, P. A., Witvliet, J., et al (1992) No direct clinical relevance of the HLA system in clozapine-induced agranulocytosis. Drug Safety, 7 (suppl.), 3–6.Google Scholar
Committee on Safety of Medicines (1990) Clozaril-induced neutropenia and the clozaril patient monitoring service. Current Problems, 30.Google Scholar
de la Chapelle, A., Kari, C., Nurminen, M., et al (1977) Clozapine-induced agranulocytosis. A genetic and epidemiologic study. Human Genetics, 37, 183–194.CrossRefGoogle ScholarPubMed
Farina, J. C., Krupp, P. & Tobler, H. J. (1978) Computer tools in spontaneous reporting of adverse drug reactions: a multinational company approach. In Conference on Computer Aid to Drug Therapy and to Drug Monitoring (eds H. Ducrot, M. Goldberg, et al), pp. 117–123. Amsterdam: North-Holland.Google Scholar
Gerson, S. T., Lieberman, J. A., Friedenberg, W. R., et al (1992) Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet, 338, 262–263 CrossRefGoogle Scholar
Heimpel, H. (1988) Drug-induced agranulocytosis. Medical Toxicology, 3, 449–462.Google Scholar
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45, 789–796.Google Scholar
Krupp, P. & Barnes, P. (1989) Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology, 99, (suppl.), 118–121.CrossRefGoogle ScholarPubMed
Lekhakula, A. & Swasdikul, D. (1991) Drug-induced agranulocytosis: experience in two university hospitals. Journal of the Medical Association of Thailand, 74, 121–129.Google ScholarPubMed
Liberman, J. A., Johns, C. A., Kane, J. M., et al (1988) Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. Journal of Clinical Psychiatry, 49, 271–277.Google Scholar
Liberman, J. A., Yunis, J., Egea, E., et al (1990) HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry, 47, 945–948.CrossRefGoogle Scholar
Liberman, J. A. & Alvir, J. M. J. (1992) A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors. Drug Safety, 7 (suppl.), 1–2.Google Scholar
Mason, R. P. & Fischer, V. (1992) Possible role of free radical formation in drug-induced agranulocytosis. Drug Safety, 7 (suppl.), 49–50.CrossRefGoogle ScholarPubMed
Pisciotta, A. V., Cronkite, C. E. & Lieberman, J. A. (1988) The cytoimmune mechanism and predictability of clozapine-induced agranulocytosis. (Abst). Blood, 72, 150.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.